Colin advises clients throughout their lifecycle (all the way from start-up/spin-out to multinational listed companies) on the commercialisation of their intellectual property rights. In particular, advising on licensing deals, collaborations and R&D projects, distribution and manufacturing and the IP, commercial and regulatory aspects of M&A, VC investments and IPOs.

Having a 1st class degree in Cell Biology his practice has naturally become focused on the life sciences, healthcare and technology (with a particular focus on med-tech and clean-tech) sectors.

显示完整简历 隐藏完整简历

最新新闻和观点

酒店与休闲

Advising gene therapy company AlveoGene on its complex spinout and launch investment

2023年10月23日

作者

点击此处了解更多
酒店与休闲

Theramex enters into an exclusive licensing agreement with Radius Health Inc to commercialise ELADYNOS®

2023年3月9日

作者 Colin McCall 以及 Charlie Adams

点击此处了解更多
酒店与休闲

Word on the street at the J.P. Morgan Healthcare Conference 2023

2023年2月1日

作者

点击此处了解更多
酒店与休闲

Advising IP Group on option exercise to accelerate development of first-in-class gene therapy for patients with cystic fibrosis

2021年10月29日

作者 Colin McCall

点击此处了解更多

与我会面: